Early access
Sign in
Enrolling by invitationNo phase

Breath Tests and Arterial Stiffness in People With Lung Diseases

Compares breath patterns and arterial stiffness in adults with chronic lung diseases and healthy adults.

Key facts

Who runs it
I.M. Sechenov First Moscow State Medical University
Where
Moscow, RussiaSee the site
Trial code
Registry title
Breath Analysis and Arterial Stiffness in Patients With Respiratory Diseases
Status
Enrolling by invitation
People taking part
400 people, planned
Started
30 Jan 2023
Expected to end
Dec 2026
Type of study
Observational, 2 groups
Treatments tested
  • Breath test using the Compact PTR-TOF-MS
  • Portable cardiac monitor "CardioQvark"
  • Assessment of arterial stiffness using the VaSera VS-1500N
Record updated
30 July 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a chronic lung disease, and also healthy adults of similar age and sex for comparison. Breath samples and heart tests are done.

Age
18 years and over
Sex
All sexes can join.
Disease stage
A clinical diagnosis of COPD, bronchial asthma, cystic fibrosis, lymphangioleiomyomatosis, hypersensitivity pneumonitis or another interstitial lung disease.

Main reasons for not taking part

  • Cannot sign the informed consent
  • Severe mental illness (severe dementia, schizophrenia, severe depression, manic-depressive psychosis)
  • Acute coronary syndrome, acute stroke or pulmonary embolism within the last 3 months
  • Cancer
  • Pregnancy

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Written informed consent to participate in the study
  • Age 18 and over
  • Clinical diagnosis of one of chronic respiratory diseases (COPD, bronchial asthma, cystic fibrosis, lymphangioleiomyomatosis, hypersensitivity pneumonitis or other interstitial lung disease)

Who cannot take part

  • Previous lung transplantation (for patients with respiratory diseases)
  • Respiratory disease (for controls)
  • Mental illness (severe dementia, schizophrenia, severe depression, manic-depressive psychosis)
  • Acute coronary syndrome, acute cerebrovascular accident, pulmonary embolism within the last 3 months
  • Diseases and conditions that can change the ECG picture and complicate the analysis of the ECG (conduction disturbance, pacemaker)
  • Inability to use a heart monitor (congenital developmental anomalies, traumatic amputation of the upper limbs, essential tremor, Parkinson's disease)
  • Unable to sign informed consent
  • Oncology
  • Pregnancy

Where in Russia

  • I.M. Sechenov First Moscow State Medical University (Sechenov University), Center "Digital biodesign and personalized healthcare"Moscow, RussiaEnrolling by invitation

About the trial

What the trial wants to find out

Assessment of cardiovascular disorders using echocardiography and arterial stiffness; comparative noninvasive assessment of volatile organic compound (eVOC) exhale breath patterns in patients with different chronic respiratory diseases with age and gender-matched healthy adults in order to identify a disease-specific exhaled eVOCs profiles and markers of respiratory and cardiovascular disorders.

The 2 groups in the trial

  • Experimental: patients with chronic respiratory diseases

    Included patients, aged ≥ 18 years, with chronic respiratory diseases: COPD, bronchial asthma, cystic fibrosis, lymphangioleiomyomatosis, hypersensitivity pneumonitis and other interstitial lung diseases. Intervention: breath analysis using the Compact PTR-MS proton mass spectrometer by Ionicon (Austria); electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor "CardioQvark"; assessment of arterial stiffness using the VaSera VS-1500N Fukuda Denshi device by non-invasive measurement of blood pressure in four limbs with simultaneous recording of electrocardiogram (ECG), phonocardiogram (PCG) and pulse waves on the carotid, femoral arteries, as well as on the arteries of four limbs. Interventions: Diagnostic Test: Breath analysis using the Compact PTR-MS proton mass spectrometer; Diagnostic Test: Portable cardiac monitor "CardioQvark"; Diagnostic Test: Assessment of arterial stiffness using the VaSera VS-1500N.

    Treatment: Breath test using the Compact PTR-TOF-MS, Portable cardiac monitor "CardioQvark", and Assessment of arterial stiffness using the VaSera VS-1500N

  • Active Comparator: Control

    Included subjects, aged ≥ 18 years. Intervention: breath analysis using the Compact PTR-MS proton mass spectrometer by Ionicon (Austria); electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor "CardioQvark"; assessment of arterial stiffness using the VaSera VS-1500N Fukuda Denshi device by non-invasive measurement of blood pressure in four limbs with simultaneous recording of ECG, phonocardiogram (PCG) and pulse waves on the carotid, femoral arteries, as well as on the arteries of four limbs. Interventions: Diagnostic Test: Breath analysis using the Compact PTR-MS proton mass spectrometer; Diagnostic Test: Portable cardiac monitor "CardioQvark"; Diagnostic Test: Assessment of arterial stiffness using the VaSera VS-1500N.

    Treatment: Breath test using the Compact PTR-TOF-MS, Portable cardiac monitor "CardioQvark", and Assessment of arterial stiffness using the VaSera VS-1500N

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Exhaled Breath Proton Mass Spectrometry and Assessment of Endothelial Dysfunction in Patients With Respiratory Diseases
Plain-language title
Breath Tests and Arterial Stiffness in People With Lung DiseasesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
30 July 2024